AMARIN CORPORATION PLC - AMERICAN DEPOSITARY SHARE

Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland China

01 Jun 2023 05:00:00 By Nasdaq GlobeNewswire

Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events

12 May 2023 10:00:00 By Nasdaq GlobeNewswire

Amarin Reports First Quarter 2023 Financial Results and Provides Business Update

03 May 2023 06:00:01 By Nasdaq GlobeNewswire

Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023

19 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors

17 Apr 2023 06:00:00 By Nasdaq GlobeNewswire

Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health

04 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)

16 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Amarin Announces Board Departures

06 Mar 2023 15:05:43 By Nasdaq GlobeNewswire

Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC

06 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event

05 Mar 2023 09:21:00 By Nasdaq GlobeNewswire

Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

01 Mar 2023 06:00:01 By Nasdaq GlobeNewswire

Amarin Announces Preliminary Voting Results Following 2023 General Meeting of Shareholders

28 Feb 2023 09:38:06 By Nasdaq GlobeNewswire

Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand

28 Feb 2023 07:00:55 By Nasdaq GlobeNewswire

Amarin Sets the Record Straight on Sarissa’s Latest Misstatements

27 Feb 2023 15:29:23 By Nasdaq GlobeNewswire

Amarin Corporation to Present New Data Evaluating VASCEPA®/VAZKEPA® (Icosapent Ethyl) at ACC.23/WCC

27 Feb 2023 07:00:02 By Nasdaq GlobeNewswire

Amarin to Present at Cowen's 43rd Annual Health Care Conference

22 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

Amarin Urges Shareholders to Vote “Against” Sarissa’s Harmful Proposals at Upcoming General Meeting – IT HAS NO PLAN, NO NEW IDEAS AND AN UNDERQUALIFIED SLATE

17 Feb 2023 08:03:50 By Nasdaq GlobeNewswire

Leading Independent Proxy Firm ISS Joins Glass Lewis in Recommending that Amarin Shareholders Vote “AGAINST” Sarissa’s Value-Destructive Proposals

16 Feb 2023 11:34:05 By Nasdaq GlobeNewswire

Amarin Clearly and Definitively Instructed Registrar to Accept ALL Submitted Proxy Cards

16 Feb 2023 08:44:16 By Nasdaq GlobeNewswire

Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Amarin Shareholders Vote “AGAINST” All of Sarissa’s Proposals

13 Feb 2023 18:47:44 By Nasdaq GlobeNewswire